The future of Pharmacy and Therapeutics formulary maintenance is the use of longitudinal, de-identified patient data. Through aggregation of data from hospital peer groups and comparative analytics, hospitals and health systems can encourage the evolution of the formulary decision-making process, enabling physicians to make drug decisions based on real-world data (RWD) and real-world evidence (RWE). The result is lower downstream healthcare costs and improved patient outcomes. Discover how NYU hospital leaders changed their approach to post-op orthopedic pain management, after RWD and RWE revealed that the drugs they had been using made little difference in length of stay and were correlated with increased opioid prescribing. The process for making drug formulary decisions is static and antiquated, based on anecdotal evidence from physicians and outdated snapshots from clinical trials. Priority is placed on cost over impact on length of stay or patient outcomes. The truth is in the data.